LAWRENCE, Mass., May 14 /PRNewswire-FirstCall/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has been recognized as the fourth largest revenue gainer in Massachusetts by the Boston Business Journal, ranked by percent change in revenue. NxStage is also the 111th company on the BBJ’s overall Massachusetts Top 150 Public Companies, ranked in terms of total 2008 revenue. The full list of the BBJ 150 appears in the May 8-14 issue of the publication.
NxStage’s Chief Executive Officer, Jeffrey H. Burbank, attributes the strong revenue growth rate to the Company’s strategic initiates to drive adoption of daily home hemodialysis with the NxStage System One™, the completion of its Medisystems acquisition and expansion of its critical care customer base. NxStage’s revenue increased nearly 115 percent to $128.8 million for the full year 2008 compared with revenue of $60.0 million for the full year 2007.
NxStage’s continued success, even in this challenging economy, speaks to the strength of the Company’s strategy and our innovative products that deliver enhanced benefits to patients and providers across the three markets we serve, stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage Medical, Inc.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end stage renal disease and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage’s System One and other products, changes in market adoption of home daily hemodialysis, and other factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Kristen K. Sheppard, Esq. VP, Investor Relations firstname.lastname@example.org
SOURCE NxStage Medical, Inc.